Home > Journals > Minerva Gastroenterologica e Dietologica > Past Issues > Minerva Gastroenterologica e Dietologica 2017 March;63(1) > Minerva Gastroenterologica e Dietologica 2017 March;63(1):62-73

CURRENT ISSUE
 

JOURNAL TOOLS

eTOC
To subscribe PROMO
Submit an article
Recommend to your librarian
 

ARTICLE TOOLS

Publication history
Reprints
Permissions
Cite this article as

 

REVIEW   

Minerva Gastroenterologica e Dietologica 2017 March;63(1):62-73

DOI: 10.23736/S1121-421X.16.02345-X

Copyright © 2016 EDIZIONI MINERVA MEDICA

language: English

Update on hepatitis C treatment: systematic review of clinical trials

Manan JHAVERI, Nicholas PROCACCINI, Kris V. KOWDLEY

Liver Care Network and Organ Care Research, Swedish Medical Center, Seattle, WA, USA


PDF


Chronic hepatitis C is a major public health problem. The chronicity of the hepatitis C can lead to advanced liver disease, cirrhosis and even hepatocellular carcinoma. Chronic hepatitis C is the leading indication of for liver transplantation in the United States. Since the introduction of directly acting antiviral agents (DAAs), there have been there have been dramatic advances in treatment of hepatitis C in terms of tolerability, duration of therapy with significant increases in the rates of sustained virologic response (SVR). This review summarizes the findings of recently published clinical trials of DAAs in the treatment of hepatitis C by genotype and in patients co-infected with HCV/HIV.


KEY WORDS: Hepatitis C - Clinical Trials as Topic - Antiviral agents

top of page